Acute Kidney Injury Clinical Trial
— oXirisOfficial title:
Comparing Cytokines, Toxins Adsorbing oXiris Filter to ST150 Filter During CRRT in Patients With Septic Shock
NCT number | NCT02600312 |
Other study ID # | oXiris |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 2015 |
Est. completion date | January 2018 |
Verified date | July 2019 |
Source | Skane University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The Oxiris® filter is a registered product for CRRT already safely used in routine care.
In in vitro experiments, the Oxiris® filter has been demonstrated to adsorb endotoxin and
cytokines. Compared to conventional filters this may be advantageous in patients with severe
sepsis but neither decreased levels of endotoxin and cytokines nor an improved outcome has
been demonstrated with clinical use.
But there are so far little clinical data on the oXiris® filter on humans. The oXiris® filter
will be investigated in a double blind randomized crossover setting against a traditional
filter (ST150). Either filter will be used for 24 hours after which it will be changed to the
opposite filter for another 24 hours.
Arterial blood samples will be drawn at start and then 1, 3, 8, 16 and 24 hours after the
start of each filter, and analyzed for endotoxin (EAA assay), TNF-α, IL-1β, IL-6 and IL-10
(ELISA) levels. Standard blood tests will be analyzed simultaneously. Data concerning mode
and settings of CRRT, heart rate, blood pressure, medication, data concerning ventilatory
support and pathogen will be registered.
Primary endpoint: Levels of endotoxin and cytokines will be compared using Student's paired
t-test on AUC values for each 24-hour period.
Status | Completed |
Enrollment | 16 |
Est. completion date | January 2018 |
Est. primary completion date | January 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Patients admitted to intensive care unit (ICU) of age >18 years with decision based on the clinical situation of the patient taken by the physician in charge that continuous renal replacement therapy will be started. 2. Vasoconstrictor and volume dependent septic shock with known Gram-negative infectious agent in blood culture. 3. Vasoconstrictor and volume dependent septic shock suspected to be caused by a Gram-negative agent and with positive plasma endotoxin test. Exclusion Criteria: 1. Infected with Hepatitis B or C or HIV. 2. Dependence on dialysis treatment before the actual ICU episode. |
Country | Name | City | State |
---|---|---|---|
Sweden | Perioperative and Intensive Care (Adult), Skåne University Hospital, Lund | Lund | Skåne |
Lead Sponsor | Collaborator |
---|---|
Skane University Hospital |
Sweden,
Ala-Kokko TI, Laurila J, Koskenkari J. A new endotoxin adsorber in septic shock: observational case series. Blood Purif. 2011;32(4):303-9. doi: 10.1159/000330323. Epub 2011 Sep 2. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | level of vasoconstrictive infusion | Need of vasoconstrictor because of shock, higher degree of shock means increased requirement of vasoconstrictor infusion. | hourly up to 48 hours | |
Primary | endotoxin level in blood | Describes the load of toxins from the septic state. Higher load means increased impact from the infectious state mediated through the septic shock. Expected mean differences in endotoxin levels including standard deviation is based on data from a previous study on extracorporeal endotoxin removal in sepsis patients (reference 1). |
change from baseline to 48 hours | |
Secondary | mean blood pressure | Additional parameter that describes the clinical impact from the septic state. | hourly up to 48 hours | |
Secondary | TNF-a level in blood | Additional parameter that describes the load from the septic shock. | change from baseline to 48 hours | |
Secondary | IL-1ß level in blood | Additional parameter that describes the load from the septic shock. | change from baseline to 48 hours | |
Secondary | IL-6 level in blood | Additional parameter that describes the load from the septic shock. | change from baseline to 48 hours | |
Secondary | IL-10 | Additional parameter that describes the load from the septic shock. | change from baseline to 48 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05538351 -
A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury
|
||
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03938038 -
Guidance of Ultrasound in Intensive Care to Direct Euvolemia
|
N/A | |
Recruiting |
NCT05805709 -
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
|
N/A | |
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|
||
Recruiting |
NCT05897840 -
Continuous Central Venous Oxygen Saturation Measurement as a Tool to Predict Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients
|
N/A | |
Recruiting |
NCT04986137 -
Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
|
||
Terminated |
NCT04293744 -
Acute Kidney Injury After Cardiac Surgery
|
N/A | |
Completed |
NCT04095143 -
Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
|
||
Not yet recruiting |
NCT06026592 -
Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
|
||
Not yet recruiting |
NCT06064305 -
Transcriptional and Proteomic Analysis of Acute Kidney Injury
|
||
Terminated |
NCT03438877 -
Intensive Versus Regular Dosage For PD In AKI.
|
N/A | |
Terminated |
NCT03305549 -
Recovery After Dialysis-Requiring Acute Kidney Injury
|
N/A | |
Completed |
NCT05990660 -
Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery
|
N/A | |
Completed |
NCT04062994 -
A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
|
||
Terminated |
NCT02860130 -
Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
|
Phase 3 | |
Completed |
NCT06000098 -
Consol Time and Acute Kidney Injury in Robotic-assisted Prostatectomy
|
||
Not yet recruiting |
NCT05548725 -
Relation Between Acute Kidney Injury and Mineral Bone Disease
|
||
Completed |
NCT02665377 -
Prevention of Akute Kidney Injury, Hearttransplant, ANP
|
Phase 3 | |
Terminated |
NCT03539861 -
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
|
N/A |